PFE · 10-Q · 2026Q3 · Full report

Operating Expense Trends

PFIZER INC · 2026-11-03 · Importance 18 · Surprise 14

Selling, informational and administrative expenses rose $93 million in the third quarter to $3.279 billion, including $100 million higher compensation costs, $40 million from a lower favorable U.S. healthcare reform fee adjustment, and $20 million of cost-realignment implementation costs. An $80 million reduction in marketing and promotional spending partly offset the quarterly increase. Nine-month SI&A increased $19 million to $9.651 billion; $190 million higher compensation, $100 million unfavorable foreign exchange, and $95 million of program implementation costs were partly offset by $190 million lower corporate enabling-function spending and $120 million lower marketing spend. Amortization of intangible assets decreased 8% in the quarter to $1.128 billion and 4% for nine months to $3.497 billion.

Key facts

• Pfizer's third-quarter 2026 selling, informational and administrative expenses increased $93 million, including $100 million higher compensation-related expenses, $40 million from a lower favorable healthcare-reform-fee adjustment, and $20 million in cost-realignment implementation costs. source
• Pfizer's first-nine-months 2026 selling, informational and administrative expenses increased $19 million, including $190 million higher compensation expenses, $100 million of unfavorable foreign exchange, and $95 million in cost-realignment implementation costs. source
• Adjusted income accounts for 40% of the bonus pool funding tied to financial performance for substantially all non-sales-force employees worldwide. source